Elucidating The Function Of Rho-ROCK Signalling In The Regulation Of Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$636,568.00
Summary
As cancers progress from benign to more malignant forms, the way in which cancer cells respond to external influences changes dramatically. These cells subvert the normal interactions between proteins which pass signals from outside the cell to the inside, to control cell behaviour and assume a survival advantage. We plan to study a form of cell signalling that is often abnormal in cancer in order to identify technologies for limiting cancer growth and spread by interfering with these signals.
Regulation Of Breast Cancer Metastasis By MiR-193b And MiR-342-3p
Funder
National Health and Medical Research Council
Funding Amount
$581,537.00
Summary
When breast cancer spreads to other organs, it results in high morbidity and mortality. MicroRNAs are a class of genes that control the expression of other genes, some of which are involved in the spread of cancer. In this project we will examine the function of two microRNA species that we have found to be associated with breast cancer spread. The anticipated outcome is a better knowledge of the genes that control cancer spread and the identification of new molecular targets for therapy.
The Ludwig Institute is adopting a two prong approach in the fight against cancer. Ludwig scientists are developing improved and sensitive scanning methods to aid in the conduct of field trials of new anti-cancer antibodies. In addition, they are also developing new targeted anti-cancer antibodies with improved properties that have the ability to bind to tumours while sparing normal tissues. These drugs can either attack the cancer directly or be used to carry drugs to the target thereby shrinki ....The Ludwig Institute is adopting a two prong approach in the fight against cancer. Ludwig scientists are developing improved and sensitive scanning methods to aid in the conduct of field trials of new anti-cancer antibodies. In addition, they are also developing new targeted anti-cancer antibodies with improved properties that have the ability to bind to tumours while sparing normal tissues. These drugs can either attack the cancer directly or be used to carry drugs to the target thereby shrinking the tumour.Read moreRead less